Pharmaceutical News

RSS

OpEds: How debt panel 'punted' on health costs; Sustainable 'doc fix;' Arizona 'death panel;' Sebelius on flu vaccine

In this Kaiser Health News column, Austin Frakt and Aaron Carroll write: "By some accounts, the Republican takeover of the House is a game changer for health reform. Already, it has reinvigorated debate over the law, and the media have focused on what federal legislators can or will do to alter it. But more attention should be directed elsewhere. The future trajectory of health reform will be shaped far more by interest group agendas and state-level actions than by the new House leadership's stated plans. Not only has the game changed, but so have the most important players" (12/9).

9 Dec 2010

Hemispherx amends Ampligen agreement with GP Pharm to include Mexico

Hemispherx Biopharma, Inc. announced that the Company has amended its June 15, 2010 agreement with GP Pharm Latinoamerica ("GP Pharm"), an affiliate company of Spanish GP Pharm SA (www.gp-pharm.com) to immediately include Mexico in the Territory under the Sales, Marketing, Distribution and Supply Agreement.

9 Dec 2010

Nacalai to distribute Techulon's Glycofect Transfection Reagent platform products in Japan

Techulon Inc., an early stage life sciences company has signed an agreement with Nacalai USA, Inc. and its parent company Nacalai Tesque, Inc. for distribution of its Glycofect Transfection Reagent platform products in Japan. Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.

9 Dec 2010

Genetic Immunity to present DermaVir and DermaPrep transdermal delivery system at HIV DART 2010 conference

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week's HIV DART 2010 conference, "Frontiers in Drug Development for Antiretroviral Therapies," in Los Cabos, Mexico. The conference brings international researchers together to discuss the latest developments in the fight against HIV/AIDS.

9 Dec 2010

Enbrel outperforms Humira in treating newly diagnosed RA patients: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer's Enbrel is the leading tumor necrosis factor -alpha inhibitor prescribed in newly diagnosed rheumatoid arthritis patients, outpacing Abbott's Humira in the first three lines of treatment.

9 Dec 2010

Medisafe 1 Technologies demonstrates syringe locking device at Israel's National Ministry of Health

Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company conducted an official demonstration of its barcoded syringe locking device at Israel's National Ministry of Health.

9 Dec 2010

Media examines efforts to protect patients in Africa from counterfeit medications

HP and the African social enterprise mPedigree on Monday announced a new service that will enable patients in Ghana and Nigeria to verify the authenticity of their medications, Fast Company reports. "Counterfeit drugs are estimated to be a $75-billion-per-year business, [and are] implicated in the deaths of something like 700,000 people around the world annually," according to the article (Zax, 12/6).

9 Dec 2010

VIRxSYS presents study results of VRX1116 at HIV DART 2010

VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies, today presented results from a study of VRX1116 at HIV DART 2010 in Los Cabos, Mexico, showing that vaccinated monkeys challenged with highly pathogenic simian immunodeficiency virus achieve sustained viral load reduction, preservation of the immune system and increased survival compared to controls.

9 Dec 2010

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

Octapharma USA researchers presented new stringent, objective criteria used in the evaluation of hemostatic efficacy in the treatment of von Willebrand disease and reported on their application of these criteria in clinical trials during the recently completed National Hemophilia Foundation Annual Meeting.

9 Dec 2010

DPT granted FDA approval to manufacture Collagenase SANTYL Ointment for wound care

DPT Laboratories, Ltd., a pharmaceutical contract development and manufacturing organization, announced today that it received FDA approval to manufacture commercial supplies of a leading sterile ointment for wound care at its Center of Excellence for Sterile & Specialty Products in Lakewood, N.J. Beginning this month, Healthpoint will ship commercial lots of Collagenase SANTYL® Ointment produced at DPT's Lakewood facility to its North American customers.

9 Dec 2010

India, EU trade agreement will not restrict ability for India's pharmaceutical firms to export generic drugs, official says

"India and the European Union (EU) have agreed that the comprehensive bilateral trade agreement being negotiated by the two will not result in an intellectual property regime that restricts the ability of Indian pharmaceutical firms to export generic or off-patent drugs by being far more stringent than the TRIPS [Trade-Related Aspects of International Property Rights] regime of the World Trade Organization," LiveMint.com reports in an article that describes recent debates over the agreement.

9 Dec 2010

Three drug companies to pay $421 million in fraud settlement

Los Angeles Times: Three pharmaceutical firms — Roxane, Abbott Laboratories and B. Braun Medical — "agreed to pay more than $421 million to settle claims of defrauding Medicare and Medicaid — the latest in a string of large healthcare fraud settlements announced by the Justice Department. The drug companies charged one set of prices to doctors and pharmacies but reported another set of inflated figures that were used as benchmarks by government insurers reimbursing healthcare providers, authorities said" (Zajac, 12/8).

9 Dec 2010

Smoking cessation products available on PBS

Australia’s federal government has announced that it will subsidize the cost of nicotine patches to help smokers quit. The announcement was made by Health Minister Nicola Roxon on Thursday who said that concession card holders would be able to access Nicorette, Nicabate P and Nicotinell under the Pharmaceutical Benefits Scheme (PBS) from February 1, 2011. She said, “Cancer scars the lives of too many Australians and we know that reducing the smoking rate is one of the most effective ways to reduce the rate of death from this terrible disease.” Anti-smoking drug Varenicline (Champix) would also be available for willing quitters.

8 Dec 2010

TOS, OAC call on FDA to address urgent need for obesity treatments

The Obesity Society (TOS) and the Obesity Action Coalition (OAC) today called on the Food and Drug Administration (FDA) to consider the urgent need for more tools to address the obesity epidemic facing more than 93 million Americans as they convene an advisory panel to review a new treatment for obesity.

8 Dec 2010

UBC's new formulation of Amphotericin B for Visceral Leishmaniasis remains stable in tropical climates

A new formulation of Amphotericin B (AmB) developed by University of British Columbia researchers has been shown to be stable in tropical climates and effective in treating Visceral Leishmaniasis (VL) in mouse models.

8 Dec 2010

Golden Living establishes in-house consulting pharmacy company

Golden Living has established a new, in-house consulting pharmacy company that will focus on improving medication safety and patient outcomes. Golden Clinical Rx Services is based on an innovative clinical pharmacist model that will make certified geriatric pharmacists (CGPs) part of the interdisciplinary clinical teams that care for Golden LivingCenter patients and will leverage technology to improve patient outcomes.

8 Dec 2010

European Commission must stop attacking generic medicines, says ITPC

On International Human Rights Day, as the European Commission (EC) and the Government of India meet in Brussels to finalise a European Union (EU)-India free trade agreement, the International Treatment Preparedness Coalition (ITPC) calls on Indian negotiators to put the right to health of its citizens and of the fifteen million HIV-positive people worldwide needing treatment above the pharmaceutical companies' interests and profits.

8 Dec 2010

Financial Times contrasts 'bottom up' and 'top down' approaches to developing country drugs

The Financial Times contrasts the model of drug development for developing countries being used by non-profit groups like the Meningitis Vaccine Project (MVP), which recently rolled out the MenAfriVac, to that of some pharmaceutical companies.

8 Dec 2010

CML patients treated with dasatinib associated with better treatment adherence, lower health costs: Study

Patients with chronic myeloid leukemia who were treated with nilotinib are found to be associated with better treatment adherence, less hospitalizations, and lower total health care costs than patients treated with dasatinib, according to a new study released by Analysis Group Inc., a leading provider of health care research and economic consulting.

8 Dec 2010

Cardinal Health continues agreement with Walgreens to supply pharmaceuticals

Cardinal Health today announced the early renewal of its distribution agreement with Walgreens to supply pharmaceuticals to its national network of retail pharmacies. The new agreement extends into 2013.

8 Dec 2010

Pharmaceutical News

OpEds: How debt panel 'punted' on health costs; Sustainable 'doc fix;' Arizona 'death panel;' Sebelius on flu vaccine

Hemispherx amends Ampligen agreement with GP Pharm to include Mexico

Nacalai to distribute Techulon's Glycofect Transfection Reagent platform products in Japan

Genetic Immunity to present DermaVir and DermaPrep transdermal delivery system at HIV DART 2010 conference

Enbrel outperforms Humira in treating newly diagnosed RA patients: Report

Medisafe 1 Technologies demonstrates syringe locking device at Israel's National Ministry of Health

Media examines efforts to protect patients in Africa from counterfeit medications

VIRxSYS presents study results of VRX1116 at HIV DART 2010

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

DPT granted FDA approval to manufacture Collagenase SANTYL Ointment for wound care

India, EU trade agreement will not restrict ability for India's pharmaceutical firms to export generic drugs, official says

Three drug companies to pay $421 million in fraud settlement

Smoking cessation products available on PBS

TOS, OAC call on FDA to address urgent need for obesity treatments

UBC's new formulation of Amphotericin B for Visceral Leishmaniasis remains stable in tropical climates

Golden Living establishes in-house consulting pharmacy company

European Commission must stop attacking generic medicines, says ITPC

Financial Times contrasts 'bottom up' and 'top down' approaches to developing country drugs

CML patients treated with dasatinib associated with better treatment adherence, lower health costs: Study

Cardinal Health continues agreement with Walgreens to supply pharmaceuticals

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News